Multiple Myeloma Coverage from Every Angle

AMG 420 T-Cell Therapy Induces Responses in Resistant Multiple Myeloma

By: Melissa E. Fryman, MS
Posted: Monday, March 9, 2020

The bispecific T-cell engager molecule AMG 420 induced responses in patients with relapsed or refractory multiple myeloma and warrants further investigation, according to a first-in-human-study conducted by Max S. Topp, MD, of the University Hospital Würzburg, Germany, and colleagues. AMG 420 is capable of binding cells that express the B-cell maturation antigen and targeting them for T-cell–mediated lysis—a therapeutic strategy considered complementary to that achieved by the use of chimeric antigen receptor (CAR) T cells. The results from this study were published in the Journal of Clinical Oncology.

In this phase I, dose-escalation study, a total of 42 patients with relapsed or refractory multiple myeloma received intravenous AMG 420 at a dose ranging from 0.2 to 800 µg/day for up to 10 6-week cycles of treatment. Of them, 25 patients discontinued participation in the study due to disease progression; 7, due to adverse events; 4, due to death; and 3 due to completion of 10 cycles; the remaining 2 patients were still being treated at the time of data analysis.

The overall response rate in this study was 31%. At the maximum tolerated dose of 400 µg/day, the response rate was 70% (7 of 10 patient responders); 800 µg/day was not a tolerable dose in this study due to grade 3 cytokine-release syndrome and polyneuropathy (one instance of each; both resolved). Of the seven patient responders receiving 400 µg/day, “five patients experienced [minimal residual disease]-negative complete responses, one had a partial response, and one had a very good partial response; all seven patients responded during the first cycle, and some responses lasted more than 1 year.”

“Results with AMG 420 show comparable response rates and onset and duration of responses as seen with CAR T cells,” the authors concluded, with fewer reported adverse events ≥ grade 3 than seen with CAR T-cell therapy.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.